Published in Curr Protein Pept Sci on October 01, 2009
α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem (2012) 2.31
Structural and functional characterization of two alpha-synuclein strains. Nat Commun (2013) 2.05
Expanding the proteome: disordered and alternatively folded proteins. Q Rev Biophys (2011) 1.60
Parkinson's disease: insights from pathways. Hum Mol Genet (2010) 1.52
Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem (2011) 1.42
Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophys J (2012) 1.42
The lipid-binding domain of wild type and mutant alpha-synuclein: compactness and interconversion between the broken and extended helix forms. J Biol Chem (2010) 1.39
Direct observation of the three regions in α-synuclein that determine its membrane-bound behaviour. Nat Commun (2014) 1.20
Mysterious oligomerization of the amyloidogenic proteins. FEBS J (2010) 1.14
Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol (2012) 1.14
Characterization of semisynthetic and naturally Nα-acetylated α-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of α-synuclein. J Biol Chem (2012) 1.13
Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs). Chem Rev (2014) 1.10
Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol Genet Metab (2012) 1.08
Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays (2010) 1.06
Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol (2009) 1.04
α-Synuclein Alters Toll-Like Receptor Expression. Front Neurosci (2011) 1.04
Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis. Cold Spring Harb Perspect Biol (2011) 1.02
Selective recruitment of an E2~ubiquitin complex by an E3 ubiquitin ligase. J Biol Chem (2012) 1.02
Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol (2011) 1.01
N-terminal acetylation of α-synuclein induces increased transient helical propensity and decreased aggregation rates in the intrinsically disordered monomer. Protein Sci (2012) 1.01
α-Synuclein: the long distance runner. Brain Pathol (2013) 0.99
Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl ester lipase gene-maturity onset diabetes of the young (CEL-MODY): a protein misfolding disease. J Biol Chem (2011) 0.99
Counteracting chemical chaperone effects on the single-molecule α-synuclein structural landscape. Proc Natl Acad Sci U S A (2012) 0.96
Specificity and kinetics of alpha-synuclein binding to model membranes determined with fluorescent excited state intramolecular proton transfer (ESIPT) probe. J Biol Chem (2011) 0.94
Gaucher disease and parkinsonism, a molecular link theory. Mol Genet Metab (2010) 0.94
Protein oxidative modifications in the ageing brain: consequence for the onset of neurodegenerative disease. Free Radic Res (2010) 0.93
Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept. Expert Rev Proteomics (2010) 0.93
Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS J (2012) 0.93
The yin and yang of amyloid: insights from α-synuclein and repeat domain of Pmel17. Phys Chem Chem Phys (2011) 0.90
Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim Biophys Acta (2009) 0.90
α-Synuclein levels are elevated in cerebrospinal fluid following traumatic brain injury in infants and children: the effect of therapeutic hypothermia. Dev Neurosci (2010) 0.88
Electrochemistry of nonconjugated proteins and glycoproteins. Toward sensors for biomedicine and glycomics. Chem Rev (2015) 0.88
Residue-specific fluorescent probes of α-synuclein: detection of early events at the N- and C-termini during fibril assembly. Biochemistry (2011) 0.88
Curcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant α-Synuclein. Sci Rep (2015) 0.86
Hydrogen-exchange mass spectrometry for the study of intrinsic disorder in proteins. Biochim Biophys Acta (2012) 0.86
Probing fibril dissolution of the repeat domain of a functional amyloid, Pmel17, on the microscopic and residue level. Biochemistry (2011) 0.86
Anti-amyloid compounds inhibit α-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA). J Biol Chem (2014) 0.86
The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease. J Neurochem (2016) 0.85
Spatial-orientation priming impedes rather than facilitates the spontaneous control of hand-retraction speeds in patients with Parkinson's disease. PLoS One (2013) 0.84
Ion Mobility Spectrometry-Mass Spectrometry of Intrinsically Unfolded Proteins: Trying to Put Order into Disorder. Curr Anal Chem (2013) 0.83
Binding of Dopamine to Alpha-Synuclein is Mediated by Specific Conformational States. J Am Soc Mass Spectrom (2013) 0.83
Covalent structural changes in unfolded GroES that lead to amyloid fibril formation detected by NMR: insight into intrinsically disordered proteins. J Biol Chem (2011) 0.82
Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators. Front Mol Biosci (2014) 0.82
In vitro aggregation assays for the characterization of α-synuclein prion-like properties. Prion (2014) 0.81
Inhibition of insulin fibrillation by osmolytes: Mechanistic Insights. Sci Rep (2015) 0.81
Defining the oligomerization state of γ-synuclein in solution and in cells. Biochemistry (2014) 0.81
Supersaturation-limited and Unlimited Phase Transitions Compete to Produce the Pathway Complexity in Amyloid Fibrillation. J Biol Chem (2015) 0.80
Molecular details of α-synuclein membrane association revealed by neutrons and photons. J Phys Chem B (2015) 0.80
Deuteration of Escherichia coli enzyme I(Ntr) alters its stability. Arch Biochem Biophys (2010) 0.80
Rifampicin and Parkinson's disease. Neurol Sci (2012) 0.79
Biophysical characterization of α-synuclein and its controversial structure. Intrinsically Disord Proteins (2013) 0.78
Emerging insights into the mechanistic link between α-synuclein and glucocerebrosidase in Parkinson's disease. Biochem Soc Trans (2013) 0.78
Transient β-hairpin formation in α-synuclein monomer revealed by coarse-grained molecular dynamics simulation. J Chem Phys (2015) 0.78
Insight into α-synuclein plasticity and misfolding from differential micelle binding. J Phys Chem B (2013) 0.78
Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn). Neuroscience (2011) 0.78
Direct Observation of α-Synuclein Amyloid Aggregates in Endocytic Vesicles of Neuroblastoma Cells. PLoS One (2016) 0.78
Dynamic New World: Refining Our View of Protein Structure, Function and Evolution. Proteomes (2014) 0.77
Biophysical Characterization of α-Synuclein and Rotenone Interaction. Biomolecules (2013) 0.77
Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson's disease (PD). Mol Brain (2016) 0.77
Intrinsic and membrane-facilitated α-synuclein oligomerization revealed by label-free detection through solid-state nanopores. Sci Rep (2016) 0.77
Sequence complexity of amyloidogenic regions in intrinsically disordered human proteins. PLoS One (2014) 0.77
Structural basis of synaptic vesicle assembly promoted by α-synuclein. Nat Commun (2016) 0.76
Structural Ensembles of Membrane-bound α-Synuclein Reveal the Molecular Determinants of Synaptic Vesicle Affinity. Sci Rep (2016) 0.76
Digested disorder: Quarterly intrinsic disorder digest (July-August-September, 2013). Intrinsically Disord Proteins (2014) 0.76
Computational analysis of fluid flow within a device for applying biaxial strain to cultured cells. J Biomech Eng (2015) 0.75
Gaucher-Associated Parkinsonism. Cell Mol Neurobiol (2015) 0.75
Dynamical Behavior of Human α-Synuclein Studied by Quasielastic Neutron Scattering. PLoS One (2016) 0.75
The C-terminal α-helices of mammalian Hsc70 play a critical role in the stabilization of α-synuclein binding and inhibition of aggregation. Int J Biol Macromol (2015) 0.75
More than a Rumor Spreads in Parkinson's Disease. Front Hum Neurosci (2016) 0.75
Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease. Drug Des Devel Ther (2017) 0.75
AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species. Curr Pharm Des (2016) 0.75
Longitudinal changes of cortical microstructure in Parkinson's disease assessed with T1 relaxometry. Neuroimage Clin (2016) 0.75
Tristetraprolin inhibits mitochondrial function through suppression of α-Synuclein expression in cancer cells. Oncotarget (2017) 0.75
Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism. F1000Res (2017) 0.75
Methods of probing the interactions between small molecules and disordered proteins. Cell Mol Life Sci (2017) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol (2005) 17.63
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature (2004) 11.82
Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci (2000) 10.62
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol (2004) 9.62
Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci (2003) 8.44
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A (1998) 8.41
A Drosophila model of Parkinson's disease. Nature (2000) 7.82
Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins (2000) 7.61
Natively unfolded proteins: a point where biology waits for physics. Protein Sci (2002) 6.91
NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry (1996) 6.47
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science (2000) 6.28
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A (2000) 5.83
Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem (1998) 5.81
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science (2000) 5.62
The influence of macromolecular crowding and macromolecular confinement on biochemical reactions in physiological media. J Biol Chem (2001) 5.57
Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med (1998) 5.49
Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature (2002) 5.32
Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci (2001) 5.32
Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol (2003) 5.00
The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron (1995) 4.78
Estimation of macromolecule concentrations and excluded volume effects for the cytoplasm of Escherichia coli. J Mol Biol (1991) 4.77
Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet (2006) 4.61
Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol (1996) 4.54
Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science (2001) 4.48
Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci (1988) 4.36
Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol (2001) 4.27
Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci (1989) 4.01
Structure and dynamics of micelle-bound human alpha-synuclein. J Biol Chem (2004) 3.87
A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol (2002) 3.87
Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A (1991) 3.85
What does it mean to be natively unfolded? Eur J Biochem (2002) 3.70
The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology (2008) 3.64
Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry (2000) 3.62
Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem (2001) 3.60
Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci (1999) 3.57
Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci U S A (2005) 3.48
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol (2004) 3.37
Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett (1998) 3.26
Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. Arch Biochem Biophys (1998) 3.21
Implications of macromolecular crowding for protein assembly. Curr Opin Struct Biol (2000) 3.20
Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci (2003) 3.15
Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J Am Chem Soc (2005) 3.13
Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem (2001) 3.13
A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J Mol Biol (2003) 2.97
Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol (2002) 2.92
Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem (1999) 2.86
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis (2002) 2.83
A broken alpha -helix in folded alpha -Synuclein. J Biol Chem (2003) 2.80
The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci (1998) 2.78
Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease? Clin Neuropathol (1985) 2.72
Guam: deadly disease dying out. Science (1993) 2.72
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
Hallervorden-Spatz syndrome. Arch Neurol (1974) 2.58
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol (2004) 2.51
Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J Biol Chem (2001) 2.49
Changes in biomolecular conformation seen by small angle X-ray scattering. Chem Rev (2001) 2.48
Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science (1987) 2.48
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol (1998) 2.47
Lewy bodies in cerebral cortex, report of three cases. Acta Neuropathol (1978) 2.41
The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry (1960) 2.40
Synucleinopathies: clinical and pathological implications. Arch Neurol (2001) 2.36
Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc Natl Acad Sci U S A (2004) 2.33
Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem (2007) 2.32
Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem (1998) 2.32
Oxidative alterations in Alzheimer's disease. Brain Pathol (1999) 2.21
Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol (1998) 2.19
The aggregation and fibrillation of alpha-synuclein. Acc Chem Res (2006) 2.17
Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett (2004) 2.16
Biological selectivity and functional aspects of protein tyrosine nitration. Biochem Biophys Res Commun (2003) 2.14
Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett (1998) 2.14
Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem (1999) 2.13
Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry (2001) 2.12
Membrane-bound alpha-synuclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles. J Am Chem Soc (2008) 2.11
Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem (2002) 2.07
Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology (2001) 2.06
Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy. Biophys J (2006) 2.05
beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron (2001) 2.05
The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci (2000) 2.03
Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem (2001) 2.03
The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J Biol Chem (2004) 2.02
Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem (2000) 2.02
Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology (1996) 2.01
NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett (1997) 2.01
The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem (2001) 1.99
Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J (1990) 1.98
The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem (2005) 1.98
Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol (1998) 1.97
The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem (2003) 1.97
Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein. J Biol Chem (2001) 1.95
Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology (1999) 1.95
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J Mol Biol (2003) 2.97
Structural basis for recognition of diubiquitins by NEMO. Mol Cell (2009) 2.73
α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem (2012) 2.31
Membrane-bound alpha-synuclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles. J Am Chem Soc (2008) 2.11
Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy. Biophys J (2006) 2.05
Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem (2008) 1.94
Identification of a copper-binding metallothionein in pathogenic mycobacteria. Nat Chem Biol (2008) 1.90
Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein. Biochemistry (2004) 1.71
The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry (2007) 1.63
Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci (2010) 1.46
Inter-helix distances in lysophospholipid micelle-bound alpha-synuclein from pulsed ESR measurements. J Am Chem Soc (2006) 1.44
Residual structure, backbone dynamics, and interactions within the synuclein family. J Mol Biol (2007) 1.43
Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein. Protein Sci (2005) 1.41
The lipid-binding domain of wild type and mutant alpha-synuclein: compactness and interconversion between the broken and extended helix forms. J Biol Chem (2010) 1.39
Identification of a helical intermediate in trifluoroethanol-induced alpha-synuclein aggregation. Proc Natl Acad Sci U S A (2010) 1.37
Characterization of semisynthetic and naturally Nα-acetylated α-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of α-synuclein. J Biol Chem (2012) 1.13
Charge neutralization and collapse of the C-terminal tail of alpha-synuclein at low pH. Protein Sci (2009) 1.12
In support of the BMRB. Nat Struct Mol Biol (2012) 1.09
Antiparallel four-stranded coiled coil specified by a 3-3-1 hydrophobic heptad repeat. Structure (2006) 1.08
Synaptic vesicles position complexin to block spontaneous fusion. Neuron (2013) 1.08
Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: α-synuclein phosphorylation at tyrosine 125. J Am Chem Soc (2012) 1.06
Folding and misfolding of alpha-synuclein on membranes. Biochim Biophys Acta (2011) 1.06
E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. J Mol Biol (2009) 1.05
Secondary structure and dynamics of micelle bound beta- and gamma-synuclein. Protein Sci (2006) 1.04
STARD4 abundance regulates sterol transport and sensing. Mol Biol Cell (2011) 1.03
c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum Mol Genet (2014) 1.03
Structural effects of Parkinson's disease linked DJ-1 mutations. Protein Sci (2008) 1.02
NMR mapping of copper binding sites in alpha-synuclein. Biochim Biophys Acta (2005) 1.01
N-terminal acetylation stabilizes N-terminal helicity in lipid- and micelle-bound α-synuclein and increases its affinity for physiological membranes. J Biol Chem (2013) 0.97
Folding of the repeat domain of tau upon binding to lipid surfaces. J Mol Biol (2006) 0.94
The unfolded state of the C-terminal domain of the ribosomal protein L9 contains both native and non-native structure. Biochemistry (2009) 0.93
Biophysics: proteins hunt and gather. Nature (2007) 0.89
The low-pH unfolded state of the C-terminal domain of the ribosomal protein L9 contains significant secondary structure in the absence of denaturant but is no more compact than the low-pH urea unfolded state. Biochemistry (2008) 0.87
The cold denatured state of the C-terminal domain of protein L9 is compact and contains both native and non-native structure. J Am Chem Soc (2010) 0.85
Folding pyrin into the family. Structure (2003) 0.84
Assigning backbone NMR resonances for full length tau isoforms: efficient compromise between manual assignments and reduced dimensionality. PLoS One (2012) 0.82
Binding of the three-repeat domain of tau to phospholipid membranes induces an aggregated-like state of the protein. Biochim Biophys Acta (2012) 0.82
Acid denaturation and anion-induced folding of globular proteins: multitude of equilibium partially folded intermediates. Curr Protein Pept Sci (2009) 0.81
Structural transitions in tau k18 on micelle binding suggest a hierarchy in the efficacy of individual microtubule-binding repeats in filament nucleation. Protein Sci (2013) 0.81
Native chemical ligation in covalent caspase inhibition by p35. Chem Biol (2006) 0.80
Structural characterization of two alternate conformations in a calbindin D₉k-based molecular switch. Biochemistry (2011) 0.78
¹H, ¹³C, and ¹⁵N backbone resonance assignments of the L124D mutant of StAR-related lipid transfer domain protein 4 (StARD4). Biomol NMR Assign (2012) 0.77